Infliximab News and Research

RSS
Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
Pneumococcal vaccinations help protect patients with rheumatoid arthritis against serious pneumococcal infections of the lungs, brain, blood, and ears

Pneumococcal vaccinations help protect patients with rheumatoid arthritis against serious pneumococcal infections of the lungs, brain, blood, and ears

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

European recommended approval of Remicade for treatment of psoriatic arthritis

European recommended approval of Remicade for treatment of psoriatic arthritis

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

FDA approves new drug Enbrel for psoriasis

FDA approves new drug Enbrel for psoriasis

500,000 patients have now been treated with REMICADE® worldwide

500,000 patients have now been treated with REMICADE® worldwide

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis